Scarica l'app Stockscreener
0.00
100.00%
-0.365
Dopo l'orario di chiusura:
.38
0.38
+
Elevation Oncology Inc Borsa (ELEV) Ultime notizie
Elevation Oncology, Inc. (NASDAQ:ELEV) Receives $3.39 Average Price Target from Brokerages - Defense World
Is Elevation Oncology Inc. a good long term investmentFree Wealth Management Insights - Autocar Professional
What drives Elevation Oncology Inc. stock priceBreakthrough stock performance - Autocar Professional
Will Elevation Oncology Inc. stock benefit from AI tech trendsHigh-return market picks - jammulinksnews.com
Elevation Oncology completes merger with Concentra Biosciences, delists from Nasdaq - Investing.com
Elevation Oncology Completes Merger with Concentra Biosciences - TipRanks
Elevation Oncology Inc. Stock Analysis and ForecastSignificant capital appreciation - Autocar Professional
Elevation Oncology, Inc.(NasdaqCM: ELEV) dropped from S&P TMI Index - MarketScreener
What analysts say about Elevation Oncology Inc. stockFree Market Dynamics Reports - jammulinksnews.com
what makes elevation oncology inc. stock price move sharplySmart Trading With Safety Margin - Newser
What makes Elevation Oncology Inc. stock price move sharplyIntraday Trade Ideas - beatles.ru
Why Elevation Oncology Inc. stock attracts strong analyst attentionMomentum Buy Alert - beatles.ru
How Elevation Oncology Inc. stock performs during market volatilityMulti Bagger Alerts - Newser
Elevation Oncology Terminates EO-3021 Study Amid Implications for Future Research and Development Strategies - AInvest
EO-3021 Study Termination: Implications for Elevation Oncology and Partners - TipRanks
Elevation Oncology Terminates License Agreement with CSPC - TipRanks
Elevation Oncology ends license agreement with CSPC Megalith Biopharmaceutical - Investing.com
Elevation Oncology, Inc. (NASDAQ:ELEV) Receives $3.39 Average PT from Brokerages - Defense World
Analyzing Ratios: Elevation Oncology Inc (ELEV)’s Financial Story Unveiled - DWinneX
Elevation Oncology, Inc. (NASDAQ:ELEV) Sees Large Decline in Short Interest - Defense World
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates FLS, ELEV, MTWO, CRKN on Behalf of Shareholders - GlobeNewswire Inc.
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Crown Electrokinetics Corp. (OTCCRKN), Elevation Oncology, Inc. (NasdaqELEV), Sitio Royalties Corp. (NYSESTR), Vigil Neuroscience, Inc. (NasdaqV - TradingView
Research Analysts Set Expectations for ELEV FY2025 Earnings - Defense World
Q2 Earnings Estimate for ELEV Issued By Leerink Partnrs - Defense World
Equities Analysts Issue Forecasts for ELEV Q3 Earnings - Defense World
Wedbush Forecasts Reduced Earnings for Elevation Oncology - Defense World
Elevation Oncology (NASDAQ:ELEV) Cut to “Hold” at TD Cowen - Defense World
HC Wainwright Downgrades Elevation Oncology (NASDAQ:ELEV) to Neutral - Defense World
Elevation Oncology (NASDAQ:ELEV) Stock Rating Lowered by HC Wainwright - Defense World
Elevation Oncology (NASDAQ:ELEV) Downgraded by HC Wainwright to Neutral - Defense World
Elevation Oncology (NASDAQ:ELEV) Receives Market Perform Rating from JMP Securities - Defense World
Elevation Oncology (NASDAQ:ELEV) Lowered to Hold Rating by William Blair - Defense World
Elevation Oncology’s (ELEV) Neutral Rating Reaffirmed at HC Wainwright - Defense World
ELEVATION ONCOLOGY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Elevation Oncology, Inc.ELEV - Business Wire
Elevation Oncology (ELEV) Receives Analyst Rating Update | ELEV Stock News - GuruFocus
This McDonald's Analyst Turns Bearish; Here Are Top 4 Downgrades For Tuesday - Benzinga
0.97%
0.22%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):